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Icodextrin-induced peritonitis: Study of five cases and compar-
ison with bacterial peritonitis.
Background. An epidemic of aseptic peritonitis related to
the presence of peptidoglycan contaminant in some batches of
icodextrin solution (Extraneal, Baxter Healthcare Corpora-
tion) occurred in Europe in the first six months of 2002.
Methods. By case-control study we examined the clinical and
biologic features of 5 patients with icodextrin-induced peritoni-
tis (group AP) and compared them with 7 patients with bacterial
peritonitis (group BP) recruited in our clinical center between
January and June 2002.
Results. Diagnosis of icodextrin-induced peritonitis was con-
firmed in all cases by a positive reintroduction test with con-
taminated batches of icodextrin. No recurrence was observed
on re-exposure to icodextrin free of peptidoglycan. Skin tests
were positive with contaminated icodextrin in 2 of 5 patients,
while they were negative with icodextrin solution free of pep-
tidoglycan (<0.6 ng/mL). During peritonitis, serum level of
C-reactive protein (CRP) was lower in group AP (42.4 ±
34 mg/L) than in group BP (135 ± 59 mg/L) (P = 0.01). Leuko-
cyte number in peritoneal dialysis effluent was lower in group
AP (284 ± 101/mm3), with a lower neutrophil/monocyte ratio
(N/M = 0.67) than in group BP (1410 ± 973/mm3; N/M = 4)
(P < 0.05). A low number of peritoneal fluid eosinophilia
(11 ± 8%) was detected in group AP.
Conclusion. Icodextrin-induced peritonitis was associated
with a burst of intraperitoneal cytokines. The phenotype of
peritoneal neutrophils was different between aseptic and bac-
terial peritonitis, indicating that inflammatory stimuli that acti-
vate neutrophils in both types of peritonitis are clearly distinct.
Finally, peritoneal injury measured by weight gain, peritoneal
permeability, and CA125 concentration seemed to be less se-
vere during icodextrin-induced peritonitis than during bacterial
peritonitis.
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Peritoneal dialysis (PD) is now an established alterna-
tive in the treatment of end-stage renal disease (ESRD).
Because peritoneal dialysis is simple to perform and is
less expensive than hemodialysis, it has gained worldwide
popularity. Ninety percent of patients who require dialy-
sis in Mexico, 50% of those in the United Kingdom, 40%
of those in Canada, and between 10% to 20% of patients
in Europe and in the United States participate in a PD
program. Approximately 130,000 patients worldwide are
maintained on chronic peritoneal dialysis [1].
Current peritoneal dialysis solutions use glucose as
the osmotic agent. However, glucose-containing solu-
tions have some disadvantages. First, the rapid absorp-
tion of glucose leads to progressive dissipation of the
osmotic gradient, so that effective ultrafiltration lasts for
only 2 to 3 hours. Second, daily absorption of glucose from
dialysate may lead to long-term metabolic complications
such as hyperinsulinemia, hyperlipidemia, and obesity.
And third, advanced glycation end-products that develop
under the influence of glucose have been incriminated
in the long-term deterioration of the peritoneal mem-
brane. Because of the need of alternative osmotic agents
to overcome the disadvantages associated with glucose-
containing solution, starch-derived glucose polymer has
been developed [2].
Icodextrin is a soluble glucose polymer derived from
maltodextrin that in turn was derived by partial hydroly-
sis of starch. It is formulated as a 7.5% aqueous solution
with electrolytes (Extraneal; Baxter Healthcare, Mau-
repas, France). It was first introduced into clinical prac-
tice in the United Kingdom in 1994 and is now currently
used by more than 9000 patients worldwide. Icodextrin
has been recently approved by the FDA. Icodextrin solu-
tion has been shown to be more effective than 1.5% and
2.5% dextrose solution in net ultrafiltration during the
long-dwell dialysis period [3, 4]. Icodextrin is expected to
be more biocompatible than glucose-based solution be-
cause it is an iso-osmotic solution with reduced glucose
degradation product content [5].
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Allergic skin reactions to icodextrin have been
reported since the beginning of its commercializa-
tion. Prevalence of the skin reactions—exfoliative or
blistering—varies from 2.5% to 15% [6, 7]. In about one
third of cases, rashes are considered serious enough to
stop icodextrin therapy. More recently, a syndrome of
sterile peritonitis has also been described in association
with icodextrin use [8–16]. In most of the cases, patients
present with cloudy dialysates and without clinical symp-
toms. Few patients have abdominal discomfort and fever.
One case experienced severe abdominal pain, diarrhea,
vomiting, and marked ultrafiltration [10]. Prevalence of
icodextrin-related sterile peritonitis is not clearly estab-
lished. The first cases were reported in 1999, and an epi-
demic of aseptic peritonitis occurred in Europe in the
first six months of 2002 [10, 14, 16, 17]. According to Bax-
ter’s pharmaco-vigilance, sterile peritonitis to icodextrin
was reported in less than 1% of patients before January
2001, while prevalence reached more than 10% during
the first six months of 2002. Investigation from Baxter
revealed that increased episodes of sterile peritonitis in
2002 were associated with a high amount of peptidogly-
can contaminant in certain batches of Extraneal [14].
Recalling contaminated batches by Baxter Healthcare
allowed the prevalence of sterile peritonitis back to de-
crease to 1%.
It is critical to recognize icodextrin-related sterile peri-
tonitis in order to avoid unnecessary antibiotic prescrip-
tion, or even catheter removal, as previously reported [8].
It is also important to gain insight into the mechanisms
involved in peritoneal inflammation to identify factors
contributing to bioincompatibility. We therefore exam-
ined the clinical and biologic features of 5 patients with
icodextrin-induced peritonitis and compared them with
7 patients with bacterial peritonitis recruited in our clin-
ical center during the same period.
METHODS
Patients
The annual peritonitis rate at the center was 37.2
in 2000 (months × patients/peritonitis) and 35.12 in
2001 (data from the Registre de Dialyse Pe´ritone´ale de
la Langue Franc¸aise). Between January 2000 and June
2001, 49 patients were undergoing peritoneal dialysis; 5
were admitted to the nephrology unit for aseptic peri-
tonitis. Peritonitis was diagnosed when cloudy effluent
was present due to an increase leukocyte count above
100/mm3. Concentrated dialysates were then cultured
on aerobe-anaerobe blood agar and chocolate agar for
5 days. Repeated cultures of the effluent and blood were
negative in these 5 patients. Icodextrin was incriminated
because recovery of peritonitis was obtained 48 hours af-
ter discontinuation of icodextrin and recurrence occurred
on re-exposure. We therefore considered that these 5 pa-
tients had aseptic peritonitis related to icodextrin. Seven
patients hospitalized in the same period for bacterial
peritonitis were studied (4 Staphylococcus epidermis, 2
Echerichia coli, and 1 Streptococcus B).
Skin tests
Two lots of icodextrin solution were used: sample
1 numbered 01J19G32 (icodextrin contamined with
10 ng/mL peptidoglycan), and sample 2 numbered
02D22G33 (icodextrin with less than 0.6 ng/mL of pepti-
doglycan).
Skin tests were performed according to the usual pro-
cedures for drug allergy [18]. Hypersensitivity reactions
were first tested by skin prick-test (SPT) using icodex-
trin solution dilution (1/10 in NaCl 4% containing phe-
nol). SPT were compared to a positive control (histamine
10 mg/mL) and to a negative control (NaCl 4% con-
taining phenol). They were analyzed after 20 minutes.
Intradermal (IDR) administration was performed with
0.05 mL of successive dilutions of icodextrin native so-
lution (1/1000, 1/100, and 1/10 in NaCl 4% containing
phenol). Tests were read by the same observer (FL). The
positivity was assessed by the presence of erythema and
wheal at 20 minutes and then 6 hours, 12 hours, 24 hours,
and reviewed at 48 hours. Results were given in median
size of papula/erythema in millimeters. All patients were
tested with sample 1. In patients with positive skin test, a
new testing with sample 1 (right arm) and sample 2 (left
arm) were performed. Five control subjects (non-atopic,
without renal disease) from the medical staff gave their
informative consent for testing sample 1 and 2 by SPT
and IDR to eliminate false-positive reaction. All 5 were
negative.
Peritoneal injury
Peritoneal permeability was studied during peritoni-
tis (day 2) and 2 months after recovery using a peri-
toneal equilibration test (PET) as previously described
[19], with slight modification. Briefly, a standardized
4-hour dwell was performed with a glucose-free but os-
motic solution—icodextrin. Dialysis fluid (30 mL) was
sampled at 0, 10, 20, 30, 60, 120, 180, 240 minutes, and
blood samples were drawn twice at 0 and 240 minutes.
Transport parameters for low-molecular-weight solutes
were calculated as mass transfer area coefficient (MTAC)
using the model of Gared [20]. For b2 microglobulin, al-
bumin, and immunoglobulin G, solute transport was cal-
culated as the peritoneal clearance, that is, the amount
of protein drained, divided by the product of the mean
of the concentration of each protein in serum and the
dwell time. The ratio:transport solute during peritoni-
tis/transport solute after recovery reflects the intensity
of peritoneal lesions [19, 21].
At the end of the PET (at day 2 and at 2 months
after recovery), 5 mL of peritoneal effluent were col-
lected for chemiluminescent determination of CA125
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concentration (Cryptor; Brahms, S’Ouen l’Aumoˆne,
France). The ratio:CA125 during peritonitis (at day 2)/
CA125 after recovery (at 2 month) reflects the intensity
of peritoneal lesions [22].
Neutrophil activation
CD11b, CD16, CD35, CD43, CD62, and CD63 ex-
pression were determined at day 2 on whole blood and
on neutrophils from peritoneal cavity. Briefly, 100 lL
of EDTA-anticoagulated blood from patients (5 × 105
neutrophils) was used for each determination. Blood
was labeled with the primary antibody (obtained from
Immunotech; Beckman Coulter, Fullerton, CA, USA)
under saturating conditions for 30 minutes at 4◦C. Non-
specific binding of antibody was determined on cells incu-
bated with an irrelevant class-matched control antibody.
Cells were washed twice with phosphate-buffered saline
(PBS) supplemented with bovine serum albumin (BSA)
(0.1%) and sodium azide (0.1%), and then labeled during
30 minutes at 4◦C with the secondary antibody (FITC-
F(ab′)2 fragments of goat anti-mouse IgG (Valbiotech,
Paris, France). Erythrocytes were lysed in 1% NaCl for
15 minutes at 4◦, and cells were fixed with 1% formalde-
hyde. Neutrophils from the peritoneal cavity were ob-
tained by centrifugation of 50 mL of the night effluent.
Neutrophils (5 × 105) were labeled as for the blood sam-
ples except erythrocytes lysis. Samples were analyzed by
flow cytometry. Analysis was focused on granulocytes,
identified by their forward and right angle scatter fea-
tures. The cut-off for positive fluorescence was the 99th
percentile of the distribution of the cells labeled with the
irrelevant antibody. The mean fluorescence intensity was
quantified on the positive population and collected by
using logarithmic amplification. Results for each recep-
tor were expressed as the ratio:peritoneal cavity mean
fluorescence/peripheral blood mean fluorescence.
Intracellular production of H2O2 by neutrophils
was determinated using the fluorescent dye 2′,7′-
dichlorofluorescin diacetate (DCFHDA), purchased
from Acros (Geel, Belgium). Neutrophils from the pe-
ripheral blood and from the peritoneal cavity effluent
were isolated by a one-step density gradient centrifuga-
tion on Polymorphprep (Nycomed, Oslo, Norway), ac-
cording to the manufacturer’s instructions. Cells were
washed and resuspended in the culture medium. Neu-
trophils (106) in 1 mL PBS, 0.1% BSA, Ca2+ 1 mmol/L,
were incubated with DCFHDA (5 lmol/L final) for
15 minutes at 37◦C. Neutrophils were immediately an-
alyzed by flow cytometry, and fluorescent emission at
510 nm was measured. Results were expressed as the
ratio:peritoneal cavity mean fluorescence/peripheral
blood mean fluorescence.
Measurement of cytokine concentrations in the peri-
toneal dialysis effluent (PDE). Sandwich enzyme-linked
immunosorbent assays were used to measure interleukin
(IL)-1, interleukin 1 receptor antagonist (IL1ra), IL-4,
IL-5, IL-6, IL-8, tumor necrosis factor-a (TNF-a), and
monocyte chemoattractant protein-1 (MCP-1) in the
PDE (R&D Systems, Minneapolis, MN, USA). Measure-
ments were made on the night effluent for 3 consecutive
days, and for each patient the value of the cytokine was
the mean of these 3 determinations. Cell-free PDE was
collected and stored at −70◦C until analysis. All sam-
ples were assayed at the same time to avoid interbatch
variation. The lowest limits of sensitivity for the assays
were 1 pg/mL (IL-1), 22 pg/mL (IL1 ra), 10 pg/mL (IL-4),
3 pg/mL (IL-5), 0.7 pg/mL (IL-6), 10 pg/mL (IL-8),
4.4 pg/mL (TNF-a), and 5 pg/mL (MCP-1). Intra-assay
coefficient of variation was less than 8% for all assays.
Statistics
The results are given as mean values ± 1 standard de-
viation unless mentioned otherwise. The data were ana-
lyzed with multivariate analysis of variance for repeated
measures. An independent samples t test and Mann-
Whitney test were also used. The statistical analysis was
made on a personal computer using Analyse it Software
(Analyse it Software, Ltd., Leeds, UK). A P value below
0.05 (two-tailed) was considered to indicate a significant
difference.
RESULTS
Aseptic peritonitis
Five episodes of aseptic peritonitis occurred in our
hospital between January and June 2002 among 49 pa-
tients maintained on chronic PD. Icodextrin solution was
used in all 5 case-patients and in 30 patients on PD. In 5
case-patients, cloudy effluent was the predominant find-
ing. Two patients had fever and abdominal pain. No skin
rash was observed. Repeated cultures of the effluent and
blood were negative. Icodextrin was incriminated in all
five patients because recovery of peritonitis was obtained
48 hours after discontinuation of icodextrin and recur-
rence occurred on re-exposure. To determine whether an
immunoallergic mechanism was involved in this reaction,
we performed skin test with icodextrin solution (sam-
ple 1, lot number 01J19G32). SPT remained negative in
all cases, while intradermal tests were positive in two of
five patients. In these two patients, wheal/flare ratio was
doubtful for dilution 1/1000 (papulas 5 and 7 mm) and
significant for dilution 1/100 with reactions of 12/18 mm
and 15/20 mm, respectively. Papulas only appeared at
6 hours, with a maximal intensity at 24 hours, and re-
mained unchanged until 48 hours.
In June 2002, we learned from Baxter Healthcare
Corporation that icodextrin solution used in our cen-
ter contained abnormal amounts of peptidoglycan. This
peptidoglycan was issued from Bacillus acidocaldarius, a
bacteria found to contaminate the starch used in the
production of icodextrin. The concentration of pepti-
doglycan in icodextrin solution varied from 3 to 10 ng
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Table 1. Clinical characteristics of the patients with bacterial (group
BP) and aseptic (group AP) peritonitis
Parameter Group BP Group AP
Patients number 7 5
Age years 76 ± 15.3 67 ± 17.6 NS
Gender F/M 5/2 2/3
Treatment time 20 ± 11 9 ± 4.2 NS
months ± SD
Modality CAPD: 6/APD: 1 CAPD: 5
Icodextrin exposure 11 ± 5 8.4 ± 4.3 NS
months
Residual diuresis 1230 ± 586 590 ± 174 P = 0.03
mL ± SD
Weight before peritonitis 71.82 ± 16.7 76.56 ± 11.0 NS
kg
Abbreviations are: APD, automated peritoneal dialysis; CAPD, continuous
ambulatory peritoneal dialysis; NS, no significance.
per milliliter (silkworm larvae plasma test [23]). Baxter
Healthcare recalled contaminated batches of Extraneal,
and we next obtained lots of icodextrin solution free of
peptidoglycan (<0.6 ng/mL). To test whether the new
icodextrin solution free of peptidoglycan might be rein-
troduced in our “allergic” patients, we first performed
skin tests with different batches of Extraneal. In the
two previously positive patients, intradermal tests were
negative with icodextrin solution free of peptidoglycan
(<0.6 ng/mL, sample 2), while they were positive with
contaminated icodextrin (10 ng per milliliter of peptido-
glycan, sample 1). We therefore reintroduced icodextrin
solution free of peptidoglycan for peritoneal dialysis in
all five patients. Intraperitoneal administrations of these
new solutions were not complicated by aseptic peritonitis.
Clinical and biologic features
To examine the clinical and biologic features of the
aseptic peritonitis, the 5 patients with icodextrin-induced
peritonitis (group AP) were matched with 7 patients with
bacterial peritonitis (group BP) recruited in our clinical
center during the same period.
Age, time on peritoneal dialysis, and duration of
icodextrin exposition were the same in both groups
(Table 1). Systemic and peritoneal inflammation was
less severe in aseptic peritonitis than in bacterial peri-
tonitis (Table 2). Serum level of CRP and leukocyte
number in peritoneal dialysis effluent was significantly
lower in group AP than in group BP (P < 0.05).
Leukocyte formula was also different, with a lower neu-
trophil/monocyte ratio in group AP (N/M = 0.67) than
in group BP (N/M = 4) (P < 0.05). Furthermore, all pa-
tients of group AP had a low number of peritoneal fluid
eosinophilia (11 ± 8%), while no patient of group BP
had eosinophils detected in peritoneal dialysis effluent
(Table 2). No peripheral eosinophilia was detected in any
patient.
Peritoneal injury
Peritonitis results in an acute injury to the peritoneal
membrane that is characterized by an increase of solute
Table 2. Biological parameters at admission of the patients during
bacterial (group BP) and aseptic (group AP) peritonitis
Parameter Group BP Group AP
Number of cells in PDE/mm3 1228.3 ± 978 284 ± 101a
Neutrophils/monocytes (PDE ratio) 4.58 ± 2.95 0.67 ± 0.55b
Eosinophils in PDE % Undetectable 11 ± 8
Systemic leukocytosis/mm3 10320 ± 3027 9700 ± 4130
CRP mg/L 135.1 ± 53.1 42.4 ± 34c
Abbreviations are: PDE, peritoneal dialysis effluent; CRP, C-reactive protein.
aP = 0.03
bP = 0.02
cP = 0.003
clearances and a release of CA125 from damaged
mesothelial cells [19, 22]. Peritoneal transport kinetic
and CA125 peritoneal dialysate concentration were
studied during peritonitis and after recovery to evaluate
peritoneal injury (Table 3). These tests have been
performed in 5 patients with bacterial peritonitis and in
only 2 patients with aseptic peritonitis. On bacterial peri-
tonitis, MTACs were higher during peritonitis than after
recovery, as indicated by the peritonitis:recovery (P:R)
ratio. As published [19], the peritonitis-induced aug-
mentation of the MTAC values was most marked for the
high-molecular-weight proteins (albumin and im-
munoglobulin G) (Table 3). In both patients with aseptic
peritonitis, albumin and IgG P:R ratios were lower than
those of patients with bacterial peritonitis. In addition,
we also found that the increment in CA125 concentration
in both patients with aseptic peritonitis was lower than
mean elevation of CA125 measured in patients with
bacterial peritonitis. Because these measurements were
performed in only two cases with aseptic peritonitis,
statistical analysis could not be made. However, weight
gain during peritonitis, which reflects alterations in the
peritoneal transport with decreased removal of water
from the body, was significantly lower in group AP than
in group BP. These results suggest that peritoneal injury
was less severe in aseptic peritonitis than in bacterial
peritonitis.
Neutrophil activation
To gain insight into the mechanism of activation of
cells found in the peritoneal cavity during peritonitis,
we examined surface expression of several receptors
on neutrophils. Neutrophil migration toward inflamma-
tory tissue sites is associated with phenotypic change.
Some membrane molecules disappear from the cell sur-
face (CD16, CD43, and CD62), while others recep-
tors increase (CD11b, CD35, CD63) [24]. These surface
transformations vary with inflammatory mediators that
activate neutrophils. On day 1 of peritonitis, surface
expression of CD11b, CD16, CD35, CD43, CD62,
CD63 of neutrophils in peripheral blood and peri-
toneal dialysis effluent were quantified by immunostain-
ing and fluorescent-activated cell sorting (FACS) analysis.
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Table 3. Peritoneal injury during bacterial (group BP) and aseptic (group AP) peritonitis
BP Group AP Group
(N = 5, mean values) (N = 2, values for the 2 patients)
P R P/R P R P/R
MTAC urea 28.7 ± 12.7 20.6 ± 6.5 1.4 ± 0.2 61.4 25.06 2.5
20.31 25.65 0.8
MTAC creat 15.6 ± 6.6 13.5 ± 5.4 1.3 ± 0.5 22.26 13.43 1.7
13.01 16.33 0.8
Cl b2m 2131 ± 423.6 1489.6 ± 725.3 1.6 ± 0.6 2533 1713 1.5
2297 1845.1 1.2
Cl Alb 171 ± 53.4 85.5 ± 19.7 2.0 ± 0.4 282.2 229.4 1.2
152.8 194.8 0.8
Cl IgG 91.5 ± 28.7 51.2 ± 14.0 1.9 ± 0.5 191.41 142.8 1.3
96.91 143.6 0.7
CA 125 U/mL 80.2 ± 61 19 ± 14.5 4.3 ± 2.1 67 27 2.5
37 23 1.6
Weight gain at admission kg 3.38 ± 0.35 (N = 7) 1.8 ± 1.25a (N = 5)
Abbreviations are: P, peritonitis; R, recovery; PR, peritonitis/recovery ratio; MTAC, mass transfer area coefficient (mL/min); Clb2m, clearance of beta-2 microglobulin
(lL/min); ClAlb, clearance of albumin (lL/min); ClIgG, clearance of immunoglobulin G (lL/min).
aP = 0.02.
Respiratory burst of neutrophils was determined by fluo-
rometry. We found that activated, peritoneal-infiltrating
neutrophils were distinct from resting, circulating neu-
trophils because they had an up-regulation of CD11b,
CD35, and CD63, a down-regulation of CD16, CD43, and
CD62, and an increased intracellular generation of hy-
drogen peroxide (Fig. 1). No difference was observed for
the markers of neutrophil degranulation (CD11b, CD35,
CD63) between group AP and group BP (Fig. 1A). In con-
trast, we found that neutrophil down-regulation of CD16,
CD43, and CD62 were significantly more pronounced
in group AP than in group BP (Fig. 1B). Generation of
respiratory burst products by peritoneal-infiltrating neu-
trophils was lower in aseptic peritonitis than in bacterial
peritonitis but the difference did not reach statistical sig-
nificance (Fig. 1C). Our results showed that inflammatory
stimuli that activate neutrophils in both type of peritonitis
are clearly distinct.
Cytokine profiles
To further investigate the mechanism involved in asep-
tic peritonitis, we measured cytokine profiles in peri-
toneal dialysate effluent. We detected high amount of
IL-1, IL-1ra, IL-6, IL-8, MCP-1, and TNF-a in dialysate
effluent of patient with aseptic peritonitis (Table 4). Con-
centrations of these cytokines were higher than those of
bacterial peritonitis. The difference was statistically sig-
nificant for IL-1ra, MCP-1, and TNF-a (Table 4). IL4 and
IL5 were not detected in dialysate effluent of patient with
aseptic and bacterial peritonitis.
DISCUSSION
Peritonitis is a major complication of peritoneal dialy-
sis. Peritonitis usually is caused by bacterial infection, but
sterile peritonitis does occur. Culture-negative peritoni-
tis may result from: (1) concomitant use of antibiotics or
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Fig. 1. Neutrophil phenotypic change associated with neutrophil trans-
migration to peritoneal cavity during bacterial peritonitis (closed bar)
and aseptic peritonitis (open bar). Surface expression of CD11b, CD16,
CD35, CD43, CD62, and CD63 on neutrophils from peripheral blood
and peritoneal dialysis effluent were quantified by immunostaining and
FACS analysis. Reactive oxygen species (ROS) production by blood and
peritoneal neutrophils were detected by flow cytometry analysis using
2′,7′-dichlorofluorescin diacetate (DCFHDA). Results are expressed
as the ratio (peritoneal cavity/blood) of mean fluorescence intensity.
Data are given as mean (bar) + SD (error bar) of at least three ex-
periments. (A) Up-regulation of CD11b, CD35, and CD63 on peri-
toneal neutrophils. (B) Down-regulation of CD16, CD43, and CD62
on peritoneal neutrophils, ∗, P < 0.05 for comparing aseptic peritoni-
tis versus bacterial peritonitis. (C) Up-regulation of ROS production by
peritoneal neutrophils. ROS production was lower in aseptic peritonitis
than in bacterial peritonitis, but not statistically significant (P = 0.06).
infection caused by non-culturable agent; (2) presence of
chemical irritants such as methylene blue, acetaldehyde,
or chlorhexidine [25–27]; (3) hypersensitivity reaction
to intraperitoneally administered heparin, antibiotics,
plasticizers, or other constituents of the peritoneal dialy-
sis system [28, 29]; or (4) contamination of dialysate so-
lution by bacterial product(s) such as endotoxin [30, 31].
Other bacterial products could lead to peritoneal inflam-
mation. In this paper, we reported an outbreak of ster-
ile peritonitis caused by peptidoglycan. Evidence such as
presence of high amount of peptidoglycan in batches of
icodextrin solution associated with peritonitis, immediate
disappearance of the symptoms after discontinuation of
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Table 4. Cytokine profile in peritoneal cavity during bacterial (group
BP) and aseptic (group AP) peritonitis
Statistical
Group BP Group AP analysis
Mean ± SD, Mean ± SD, (Mann-Whitney
(N = 5) (N = 4) test)
IL-1 pg./mL 6.9 ± 9.1 42 ± 4.63 NS
IL-1ra pg./mL 465.4 ± 142.8 3925 ± 3486.2 P = 0.01
IL-4 pg./mL <10 <10 –
IL-5 pg./mL 2.1 ± 0.8 4.4 ± 3.2 NS
IL-6 pg./mL 2036 ± 1606.1 14803 ± 16646 NS
IL-8 pg./mL 462 ± 592 2637.5 ± 2360.3 NS
MCP-1 pg./mL 748.4 ± 293.8 7843.7 ± 7308 P = 0.03
TNF pg./mL 3.1 ± 1.7 42.7 ± 36 P = 0.01
Abbreviations are: IL, interleukin; IL-1ra, interleukin 1 receptor agonist;
MCP-1, monocyte chemoattractant Protein-1; TNF, tumor necrosis factor; NS,
not significant.
contaminated icodextrin, and absence of recurrence on
re-exposure to icodextrin-free of peptidoglycan, strongly
suggest the role of peptidoglycan as the etiologic factor
in this aseptic peritonitis. Interestingly, a recent paper re-
ported recurrence of sterile peritonitis on rechallenging
with new batches of icodextrin [32]. One explanation may
be that the batches of icodextrin used for rechallenge still
contained very low amount of peptidoglycan. Although
since June 2002, Extraneal batches are guaranteed to
contain less than 7.4 ng/mL of peptidoglycan, they are
not guaranteed to be free of peptidoglycan. It is therefore
possible that a very low concentration of peptidoglycan
that is not sufficient to induce immunization may induce
an immunologic response in sensitized patients.
Peptidoglycan is a component accounting for about
70% and 20% of the Gram-positive and Gram-negative
bacterial cell wall, respectively. The main structural fea-
tures of peptidoglycan are linear glycan chains inter-
linked by short peptides. These molecules, produced
exclusively by bacteria, belong to the pathogen-
associated molecular patterns (PAMPs) family [33].
Other examples of PAMPs are lipopolysaccharide (LPS),
bacterial lipoprotein, and lipoteichoic acids. PAMPs are
recognized by germline-encoded receptors on the surface
of cells of the innate immune system. Toll-like receptor
(TLR) proteins, homologs of the Drosophila protein Toll,
have been found on the surface of mammalian cells and
are important in the responses of phagocytes to PAMPs.
TLR4 is critical for the response to lipopolysaccharide
(LPS) of Gram-negative bacteria, while TLR2 is im-
portant for response to peptidoglycan of Gram-positive
bacteria [33]. It is therefore possible that peptidoglycan
induced peritoneal inflammation by binding to TLR2 ex-
press on cells of the innate immune system. Delayed type
hypersensitivity to peptidoglycan is another mechanism
that may also explain peptidoglycan-induced peritoni-
tis. Immunization to peptidoglycan has been described
[34, 35]. High amounts of peritoneal cytokines and pre-
dominance of peritoneal monocytes are compatible with
both hypotheses. But positive skin tests obtained with
very low amount of peptidoglycan (1/1000 dilution) and
presence of peritoneal eosinophils during peritonitis ar-
gue for an allergic reaction. In addition, the fact that only
5 patients among 30 receiving the same batches of icodex-
trin experienced peritonitis is consistent with an immuno-
allergic process. Determination of the mechanism leading
to peptidoglycan-induced peritonitis will require further
investigations.
Even if it has been recently questioned [36], peritoneal
inflammation observed during infection seems to be a ma-
jor factor in reducing the life span of the membrane [37].
In the present study, peritoneal injury was evaluated by
increment in permeability, CA125, and weight gain. In
group AP, PET were only performed for 2 patients, so
statistical analysis was not performed. Interestingly, aug-
mentation of the MTAC of high-molecular-weight pro-
teins and in CA125 levels was lower in these two patients
compared with mean values obtained in BP group. This
could indicate a less severe peritoneal injury in AP than
in BP group, or at the opposite long-term impairment of
peritoneal membrane in AP group. We found no clinical
evidence in our patients that the peritonitis episode had
caused irreversible damage to the peritoneum. In addi-
tion, weight gain was lower in AP group, despite the poor
residual renal function. Taken together these results sug-
gest a less severe acute peritoneal injury during aseptic
peritonitis.
Icodextrin-induced peritonitis was associated with a
burst of intraperitoneal cytokines. The high level of
MCP-1 may account for the high number of mono-
cytes. Despite high amounts of IL-8, a major neutrophil
chemoattractant, the number of peritoneal neutrophils
was lower in aseptic peritonitis than in bacterial peritoni-
tis. These data suggest that other chemoattractants such
as bacterial products (formylated peptides and LPS) may
also play a role in neutrophil recruitment during bacte-
rial peritonitis. Moreover, we found that the phenotype of
transmigrated neutrophils was different between aseptic
and bacterial peritonitis. This result indicates that acti-
vation signals leading to neutrophil activation and peri-
toneal inflammation are clearly distinct between both
types of peritonitis. Tissue damage after acute bacterial
infection partly result from excessive neutrophil infiltra-
tion and activation in the infected tissue [24]. Data from
the literature suggest that peritoneal injuries during peri-
tonitis are mediated by neutrophils [38]. The low num-
ber of neutrophils and the poor reactive oxygen species
production by peritoneal infiltrating neutrophils during
aseptic peritonitis may account for the weak peritoneal
damage observed during icodextrin-induced peritonitis.
It is interesting to note that despite a burst of intraperi-
toneal cytokines, aseptic peritonitis are associated with
a small inflow of activated neutrophils and a weak peri-
toneal damage.
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CONCLUSION
Our study shows that icodextrin-induced peritonitis
was associated with: (1) a contaminating peptidoglycan in
some batches of icodextrin; (2) a burst of intraperitoneal
cytokines; (3) a small inflow of activated neutrophils; and
(4) weak peritoneal damage. Further investigations are
needed to determine whether peritoneal inflammation
result from direct activation of cells of the innate immune
system by peptidoglycan, or from delayed type hypersen-
sitivity to peptidoglycan.
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